Press Releases Year None20202019201820172016 Nov 30, 2020 Imara to Present Clinical Data on IMR-687 as Monotherapy and in Combination with Hydroxyurea in Patients with Sickle Cell Disease at the 62nd ASH Annual Meeting and Exposition Nov 17, 2020 Imara Announces the Appointment of Lynette Hopkinson as Senior Vice President of Regulatory Nov 05, 2020 Imara Reports Third Quarter 2020 Financial Results and Business Highlights Oct 29, 2020 Imara to Webcast Conference Call of Third Quarter Financial Results Oct 16, 2020 Imara Announces First Patient Dosed in Forte Phase 2b Clinical Trial of IMR-687 in Beta-Thalassemia Sep 02, 2020 Imara to Present at Upcoming Investor Conferences Aug 25, 2020 Imara Receives Orphan Drug Designation from the European Commission for IMR-687 for the Treatment of Sickle Cell Disease Aug 14, 2020 Imara Reports Second Quarter 2020 Financial Results and Business Highlights Aug 13, 2020 Imara Announces First Patient Dosed in Ardent Phase 2b Clinical Trial of IMR-687 in Sickle Cell Disease Aug 07, 2020 Imara to Webcast Conference Call of Second Quarter 2020 Financial Results Pagination Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 22
Press Releases Year None20202019201820172016 Nov 30, 2020 Imara to Present Clinical Data on IMR-687 as Monotherapy and in Combination with Hydroxyurea in Patients with Sickle Cell Disease at the 62nd ASH Annual Meeting and Exposition Nov 17, 2020 Imara Announces the Appointment of Lynette Hopkinson as Senior Vice President of Regulatory Nov 05, 2020 Imara Reports Third Quarter 2020 Financial Results and Business Highlights Oct 29, 2020 Imara to Webcast Conference Call of Third Quarter Financial Results Oct 16, 2020 Imara Announces First Patient Dosed in Forte Phase 2b Clinical Trial of IMR-687 in Beta-Thalassemia Sep 02, 2020 Imara to Present at Upcoming Investor Conferences Aug 25, 2020 Imara Receives Orphan Drug Designation from the European Commission for IMR-687 for the Treatment of Sickle Cell Disease Aug 14, 2020 Imara Reports Second Quarter 2020 Financial Results and Business Highlights Aug 13, 2020 Imara Announces First Patient Dosed in Ardent Phase 2b Clinical Trial of IMR-687 in Sickle Cell Disease Aug 07, 2020 Imara to Webcast Conference Call of Second Quarter 2020 Financial Results Pagination Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 22
Nov 30, 2020 Imara to Present Clinical Data on IMR-687 as Monotherapy and in Combination with Hydroxyurea in Patients with Sickle Cell Disease at the 62nd ASH Annual Meeting and Exposition
Nov 17, 2020 Imara Announces the Appointment of Lynette Hopkinson as Senior Vice President of Regulatory
Oct 16, 2020 Imara Announces First Patient Dosed in Forte Phase 2b Clinical Trial of IMR-687 in Beta-Thalassemia
Aug 25, 2020 Imara Receives Orphan Drug Designation from the European Commission for IMR-687 for the Treatment of Sickle Cell Disease
Aug 13, 2020 Imara Announces First Patient Dosed in Ardent Phase 2b Clinical Trial of IMR-687 in Sickle Cell Disease
